about
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma.Does hepatitis C virus cause severe liver disease only in people who drink alcohol?Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue.Infections and solid organ transplant rejection: a cause-and-effect relationship?Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.Initial antiretroviral therapy in chronically-infected HIV-positive adults.AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.Liver diseases in developing countries.Human immunodeficiency virus-associated peripheral neuropathies.Infections and thalassaemia.Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.Hepatitis C virus and human immunodeficiency virus transmission routes: Differences and similaritiesHepatitis C virus infection in the elderly: epidemiology, natural history and management.Lung infections after cancer chemotherapy.Management of chronic hepatitis B in children: an unresolved issue.Liver disease in patients with HIV in sub-Saharan Africa.Can HIV-1 viral interference be used therapeutically?Treatment of Acute Liver Failure in Resource-Constrained Settings without Transplantation Facilities Can Be ImprovedAutoimmune hepatitis type 2 induced by HCV and persisting after viral clearance.Clinical course of infection with hepatitis C.Childhood infections and autoimmune diseases.MHC class I molecules and progression to AIDS.Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B.Mortality due to hepatitis C virus-related cirrhosis in patients infected with HIV type 1: a role for alcohol.Full adherence to HAART: is it really necessary?Effect of pregnancy on chronic hepatitis C.End-stage liver disease in eastern Europe and central Asia: action is needed.Hepatitis C is not a sexually transmissible disease.Time for universal HIV and HBV screening for patients with cancer.Sequelae and serologic outcome in persons with hepatitis B virus infection.Limited adherence to antiretroviral regimens in an Italian Cohort: a long-term follow-up.Childhood hepatitis C virus infection.Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes.Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals.The challenge of lymphomas in sub-Saharan Africa.Lymph nodes and pathogenesis of infection with HIV-1.Antiretroviral therapy in low-resource settings.Is there a role for viruses in triggering autoimmune hepatitis?Goodbye, Botswana!
P50
Q30380999-6D5D7122-7A40-473B-890F-DF997A774A7DQ34683615-8B21485A-FCA4-41B5-BB5A-86F890C926C4Q34727697-FE2778AA-961B-4282-8AD6-CA2ED0BB86E9Q34807471-6B0DA0B2-7CEE-4ACC-8FAB-BB9864917FFEQ35557446-CB0DAB71-0252-4795-91C5-C8120BE7FB3AQ35688173-02F2DCFA-AE5A-4F06-95C5-0F7CD0898A7AQ35776693-307383AC-9DF7-423D-AD79-95028DF181DDQ35875831-C5DACDC2-A6C9-4209-B9D9-3D6DF606CA58Q36393130-D99392BE-46AD-471B-B62C-28B927DE546BQ36428718-17B5B364-68A3-4F0B-BCAF-CE4D5FA9B025Q36548076-0754A32B-8DEE-427D-8076-73B8882606CEQ36876376-FCB7918E-063C-4673-A6EA-18497D34EEF1Q37053802-34B1A16B-AAB3-4067-B257-E17C047ED6ACQ37345694-FEF3AADD-D2DC-4ADF-8302-E0E099944CF7Q38215076-A5348591-6DC4-4F34-B72B-65F21D8CDFF0Q38928888-8C25CD4E-7876-475B-8D14-0F0EDDC92953Q40796409-6F61C947-057E-460C-B535-5BD4CBDEDA30Q42428675-B5D48099-06F2-4FFA-A250-64571934007BQ42985293-7BD4E185-4E77-450A-A9E1-1325BC356B2EQ43207595-24987598-7049-43EE-A401-8E98FB4BA55BQ43457251-F309A1A9-D786-4EAB-A3F4-2BB6D1B4438AQ43606404-9C10ADE6-7A74-44AF-9FAB-10DCBE4367EFQ43618426-21F7106F-0077-413A-B6A2-3D2ED6B21640Q43771801-C5DE9612-BB67-4387-A27A-F7C97C3B820BQ43783754-981D3D20-9EFC-4EE4-B323-AC2CD364690DQ43828663-A0D504BB-9A05-4028-B7FC-46F6CEBA849DQ44038806-29D80971-EF36-4F0B-B24E-B2F5C7F2B56CQ44082231-44F9C1A6-98EA-45B7-AE1D-58EF15591BA1Q44301025-4458FFF3-D602-4D2A-B8D6-BBC5AC2DDD0DQ44387007-507EF4E0-46AC-4A8B-8591-2919C1F0C248Q44760984-5745D293-37A5-4675-AA43-1B087277F2BDQ45421839-6148FE01-5E5A-46F2-B385-EDD2B49AA3F6Q45741531-9813C5B8-270E-4E79-8E96-5E7147196DEAQ45772528-DBCAC9FD-2BC4-45C0-A949-AD4A8D168490Q45787469-4936EC3F-ADE1-477B-83B2-6105A191CF44Q46233092-3427706B-B62E-41C8-A9E7-E89D70972770Q46470432-C4C6A378-01C0-49FD-A1B8-97361F6386EBQ46664661-C355D1A8-6B43-41B0-A64B-4532061D50A7Q50101314-A0F6401B-15F8-45C7-B48F-62F438611D08Q51367037-BBBF4023-7BCF-4269-8BEC-7A2AB1028C9E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesca Cainelli
@ast
Francesca Cainelli
@en
Francesca Cainelli
@es
Francesca Cainelli
@nl
Francesca Cainelli
@sl
type
label
Francesca Cainelli
@ast
Francesca Cainelli
@en
Francesca Cainelli
@es
Francesca Cainelli
@nl
Francesca Cainelli
@sl
prefLabel
Francesca Cainelli
@ast
Francesca Cainelli
@en
Francesca Cainelli
@es
Francesca Cainelli
@nl
Francesca Cainelli
@sl
P106
P21
P31
P496
0000-0003-1838-3946